In February, the Global Liver Institute organized and hosted a webinar dedicated to paediatric and rare liver diseases in Europe, with the scope to highlight the complexities in terms of diagnosis, treatment, care pathways, impacts upon the family, transition to adulthood (read also our relevant publication).
Experts estimate that liver diseases affect up to 1 in 10 children across Europe and are often diagnosed at a late stage since early symptoms largely go undetected. Chronic liver diseases developed at a young age necessitate long-term treatment with life-changing consequences.
This event focused on the novel advances in rare and undiagnosed liver diseases, aiming to outline the burden of liver diseases, their complexity, the unmet needs of the patients and their families, as well as the opportunities to learn more about pathophysiological mechanisms and targets, using specific examples.
Prof. Carlo Dionisi-Vici from the Bambino Gesù Children’s Hospital in Rome (member centre of MetabERN) was among the speakers of the event, which was co-hosted by EASL (European Society for the Study of the Liver) and endorsed by MetabERN (European Reference Network for Hereditary Metabolic Diseases), LPI (Liver Patients International) and the PBC Foundation.
